Although precision medicine has had a mixed impact on the clinical management of
patients with advanced-stage cancer overall, for NSCLC, and more specifically for lung …

… Peled graduated medical school, with an MD/Ph.D. degree, at the Rappaport Faculty of
medicine, Technion—Israel Institute of Technology (Haifa, Israel), in 1994. Dr, Peled focuses on …

The isolation and analysis of circulating cell-free tumor DNA in plasma is a powerful tool with
considerable potential to improve clinical outcomes across multiple cancer types, including …

Background Pembrolizumab is a humanized monoclonal antibody against programmed
death 1 (PD-1) that has antitumor activity in advanced non–small-cell lung cancer (NSCLC), …

Background First-line therapy for advanced non–small-cell lung cancer (NSCLC) that lacks
targetable mutations is platinum-based chemotherapy. Among patients with a tumor …

… different regarding KRAS mutation subtype if we compare G12C (n = 100) to other mutations
(n = 143, P = 0.47) or G12D (n = 39) versus other KRAS mutations (n = 204, P = 0.40). PFS …

KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously
reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups of …

… , n = 12; third or later line, n = 3), for a crossover rate of 64.2% (97 of 151 patients) in the
intent-to-treat population and an effective crossover rate of 65.1% (97 of 149 patients) excluding …

… A total of 305 patients were enrolled and randomly assigned to receive pembrolizumab
monotherapy (n = 154) or chemotherapy (n = 151; Fig ​1). All patients except one in the …

… Overall, 616 patients were randomly assigned to pembrolizumab plus pemetrexed-platinum
(n = 410) or placebo plus pemetrexed-platinum (n = 206). Patient demographics and …